Literature DB >> 20087954

Correlates of NT-proBNP concentration in patients with essential hypertension in absence of congestive heart failure.

Keizo Toda1, Yukihito Sato, Tomoko Hara, Kenro Hijiya, Ryutaro Kaneko, Tatuo Okada, Yoshiki Takatsu, Hisayoshi Fujiwara, Toshiaki Iwasaki.   

Abstract

BACKGROUND: N-terminal proBNP (NT-proBNP) is widely used as a diagnostic biomarker and for the risk stratification of patients with heart failure (HF). Its role in the evaluation of patients with essential hypertension (EHT) is less clear. We examined the relationship between NT-proBNP concentrations and various clinical characteristics in hypertensive patients without HF.
METHODS: This study included 186 consecutive patients with EHT and no history of HF, ischemic heart disease, or atrial fibrillation. Single and multiple variable regression analyses were performed in search of clinical correlates of NT-proBNP concentrations.
RESULTS: In patients with EHT, median serum concentration of NT-proBNP was 73 pg/ml, and interquartile range (IQR) was 40-128 pg/ml. NT-proBNP was significantly higher (P<0.001) in women (87 pg/ml; IQR 55-137 pg/ml) than in men (52 pg/ml; IQR 24-115 pg/ml). Age (r=0.371, P<0.001), precordial QRS voltage (r=0.223, P<0.001), hemoglobin (Hgb) concentration, (r=-0.208, P=0.023) and estimated glomerular filtration rate (r=-0.139, P=0.044) were correlated with log-transformed NT-proBNP by multiple variable analysis. In men, age (r=0.453, P<0.001) and QRS voltage (r=0.283, P=0.004), and in women age (r=0.299, P=0.006), QRS voltage (r=0.212, P=0.019), Hgb (r=-0.182, P=0.049), and estimated glomerular filtration rate (r=-0.272, P=0.009) were correlated with serum concentrations of NT-proBNP.
CONCLUSIONS: Age, gender, Hgb, left ventricular hypertrophy and renal function were correlated with NT-proBNP in patients with EHT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20087954      PMCID: PMC6647708          DOI: 10.1002/jcla.20366

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  19 in total

1.  National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure.

Authors:  Fred S Apple; Alan H B Wu; Allan S Jaffe; Mauro Panteghini; Robert H Christenson; Christopher P Cannon; Gary Francis; Robert L Jesse; David A Morrow; L Kristen Newby; Alan B Storrow; W H Wilson Tang; Franca Pagani; Jillian Tate; Jordi Ordonez-Llanos; Johannes Mair
Journal:  Circulation       Date:  2007-07-14       Impact factor: 29.690

2.  N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.

Authors:  Caroline Kistorp; Ilan Raymond; Frants Pedersen; Finn Gustafsson; Jens Faber; Per Hildebrandt
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

3.  Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism.

Authors:  F Liang; D G Gardner
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

4.  Association between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with hypertension.

Authors:  M Suzuki; K Yamamoto; S Watanabe; T Iwata; M Hamada; K Hiwada
Journal:  Am J Med       Date:  2000-06-01       Impact factor: 4.965

5.  Myocyte cell loss and myocyte cellular hyperplasia in the hypertrophied aging rat heart.

Authors:  P Anversa; T Palackal; E H Sonnenblick; G Olivetti; L G Meggs; J M Capasso
Journal:  Circ Res       Date:  1990-10       Impact factor: 17.367

6.  Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure.

Authors:  Paul M McKie; Richard J Rodeheffer; Alessandro Cataliotti; Fernando L Martin; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Margaret M Redfield; John C Burnett
Journal:  Hypertension       Date:  2006-04-03       Impact factor: 10.190

7.  Plasma brain natriuretic peptide concentration: impact of age and gender.

Authors:  Margaret M Redfield; Richard J Rodeheffer; Steven J Jacobsen; Douglas W Mahoney; Kent R Bailey; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

8.  Clinical significance of B-type natriuretic Peptide in the assessment of untreated hypertension.

Authors:  Shingo Seki; Tetsuji Tsurusaki; Tokuo Kasai; Ikuo Taniguchi; Seibu Mochizuki; Michihiro Yoshimura
Journal:  Circ J       Date:  2008-05       Impact factor: 2.993

9.  Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects.

Authors:  Roland R J van Kimmenade; James L Januzzi; Jaap A Bakker; Alphonse J Houben; Roger Rennenberg; Abraham A Kroon; Harry J G M Crijns; Marja P van Dieijen-Visser; Peter W de Leeuw; Yigal M Pinto
Journal:  J Am Coll Cardiol       Date:  2009-03-10       Impact factor: 24.094

10.  Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure.

Authors:  Jochem Hogenhuis; Adriaan A Voors; Tiny Jaarsma; Arno W Hoes; Hans L Hillege; Johannes A Kragten; Dirk J van Veldhuisen
Journal:  Eur J Heart Fail       Date:  2007-05-25       Impact factor: 15.534

View more
  2 in total

1.  Variability of NT-proBNP and its relationship with inflammatory status in patients with stable essential hypertension: a 2-year follow-up study.

Authors:  Esther Roselló-Lletí; Jose R Calabuig; Pedro Morillas; Raquel Cortés; Luis Martínez-Dolz; Luis Almenar; Jose R González-Juanatey; Catheline Lauwers; Antonio Salvador; Manuel Portolés; Vicente Bertomeu; Miguel Rivera
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

2.  Relationship between left ventricular geometry and soluble ST2 in a cohort of hypertensive patients.

Authors:  Dike B Ojji; Lionel H Opie; Sandrine Lecour; Lydia Lacerda; Olusoji Adeyemi; Karen Sliwa
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-10-30       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.